Medical BeneHold™ CHG Antimicrobial Adhesive Technology

Introducing a customizable antimicrobial skin-contact adhesive technology platform

An opportunity to deliver antimicrobial performance in skin-contact adhesive products from a leader in materials science

Chlorhexidine gluconate (CHG) was selected by Avery Dennison Medical as the antimicrobial of choice owing to its widespread use and acceptance as a skin antiseptic in hospital settings. The BeneHold CHG antimicrobial adhesive platform combines this effective antimicrobial agent with Avery Dennison Medical’s well-established expertise in skin-contact adhesives, allowing for the development of unique products in a variety of medical applications with our partners.

Proprietary BeneHold™ CHG Antimicrobial Adhesive Technology

- Incorporates CHG directly into the adhesive
- Eliminates the need for an additional component to hold and deliver the antimicrobial
- Offers broad spectrum antimicrobial efficacy
- Allows for contact layer to remain transparent and thin
- Allows for full visualization of the site (when required for the application)
- Option to tailor adhesion and fluid management performance to meet application requirements
- Enables customization to meet user requirements
Applications
BeneHold CHG Antimicrobial Adhesive Technology can be customized for a variety of applications and performance requirements. In existing commercial products, it has been designed to address applications requiring long wear time and sustained antimicrobial efficacy up to 7 days.

Commercial Partnerships
- Vascular Access: BD ChloraShield™ IV dressings
- Post-operative dressings: ReliaTect® Post-Op Dressing with CHG from Eloquest Healthcare®

Partnership Opportunities
- Post-op dressing
  - For our post-operative dressings, we are currently seeking a partner(s) for marketing and distribution outside of the United States and Canada, which are currently exclusively licensed.
  - Features include:
    - Sustained antimicrobial efficacy, throughout 7-day wear
    - Transparency for undisturbed site visualization
    - Manages low to moderate exudate without needing a pad
    - Waterproof
    - Barrier to external contaminants

- Applications targeted for expansion:
  - We are looking to expand into additional applications outside of our current product lines with a development partnership. We will work closely with our partner to develop and commercialize new products utilizing our BeneHold CHG adhesive technology.
  - Current targets include:
    - Surgical
    - Negative pressure wound therapy
    - Advanced wound care
  - We are not limited to only these applications. If you have an idea for a product application outside of those listed, we would like to discuss partnership opportunities with you.

Partner with us to develop unique products with BeneHold™ CHG Antimicrobial adhesive technology. If you are interested in marketing and distributing our post-op dressing outside of the United States and Canada, or are interested in developing a new product for another medical application, connect with our team to learn more.

CONNECT WITH US FOR MORE INFORMATION!

Barbara Van Rymenam, Global Director, CHG Program Management
mobile: +32 (0)497103233
e-mail: barbara.van.rymenam@eu.averydennison.com
website: www.medical.averydennison.com

Colleen Hyman, Global Product Manager, CHG Platform
mobile: +1 440-754-9201
e-mail: colleen.hyman@averydennison.com
website: www.medical.averydennison.com

©2019, Avery Dennison Corporation, Avery Dennison, BeneHold, and the triangle logo are registered trademarks of Avery Dennison Corporation. All rights reserved. All other trademarks are the property of their respective owners.
Eloquest Healthcare® and ReliaTect® are registered trademarks of Ferndale IP, Inc.
BD and BD ChloraShield are property of Becton, Dickinson and Company.
Products described may be covered under one or more pending or granted patents.
GBL-MKT-000092-A